Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Stock Chart & Stats
$57.80
-$4.21(-8.86%)
At close: 4:00 PM EST
$57.80
-$4.21(-8.86%)
Day’s Range― - ―
52-Week Range$22.28 - $59.55
Previous CloseN/A
Volume7.58M
Average Volume (3M)11.80M
Market Cap
$19.68B
Enterprise Value$22.45B
Total Cash (Recent Filing)$5.80B
Total Debt (Recent Filing)$1.92B
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Apr 30, 2026EPS Estimate
-2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding394,939,420
10 Day Avg. Volume9,544,333
30 Day Avg. Volume11,804,828
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue11.56
Enterprise Value/Gross Profit81.94
Enterprise Value/Ebitda-8.80
Forecast
1Y Price Target
$36.13Price Target Upside-37.49% Downside
Rating ConsensusHold
Number of Analyst Covering18
EPS Forecast (FY)-6.44
Revenue Forecast (FY)$2.06B
Bulls Say, Bears Say
Bulls Say
Financial Discipline And Cash BurnReduced operating expenses and improved working capital lower cash burn and support a multi‑year path to breakeven, increasing runway for pivotal late‑stage programs.
Flu Regulatory ReviewFDA acceptance of the biologics application for the mRNA flu vaccine creates a clear regulatory review pathway and reopens the opportunity to capture a portion of the U.S. flu market for older adults.
Oncology Clinical ReadoutPositive clinical data for intismeran in adjuvant melanoma could validate an oncology franchise and materially diversify revenue away from infectious disease vaccines.
Bears Say
Appellate Contingent LiabilityA contingent appellate risk over government‑contractor immunity could require additional payments if courts rule against the company, leaving material financial exposure.
Market Valuation RiskRecent share gains may overvalue near‑term pipeline prospects amid weakening demand for COVID products and ongoing headline risk, exposing the stock to downside if trials or approvals disappoint.
Patent Litigation Over Next‑generation BoosterA newly filed patent lawsuit alleging the next‑generation booster copies a rival design increases legal uncertainty and the risk of damages or ongoing royalty obligations.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $59.55 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $19.68B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Apr 30, 2026 which is in 55 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Feb 13, 2026. The company reported -$2.11 earnings per share for the quarter, beating the consensus estimate of -$2.544 by $0.434.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.03.
How many shares outstanding does Moderna have?
Moderna has 394,939,420 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$2.11 in its last earnings report, beating expectations of -$2.544. Following the earnings report the stock price went up 5.285%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$36.13 (-37.49% Downside)
$36.13 (-37.49% Downside)
Blogger Sentiment
Bullish
MRNA Sentiment 84%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 55.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $703.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 56%
Bearish news 44%
Bearish news 44%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.61%
12-Months-Change
Fundamentals
Return on Equity
-28.87%
Trailing 12-Months
Asset Growth
-12.76%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights meaningful operational and commercial progress — notably strong MNEXT Spike launch, substantial cost reductions (operating expenses down 30%, cost of sales down 41%, R&D down 31%), improved losses and a healthy cash balance — alongside multiple clinical and commercial catalysts (fully enrolled late‑stage trials, strategic partnerships, international filings). Major risks include the FDA refusal to file for the flu vaccine, continued net losses and cash runoff toward 2026, and reliance on event‑driven readouts and international approvals for growth. Overall, the company demonstrated strong execution and cost discipline but faces material regulatory and timing risks that temper near‑term visibility.View all MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$36.13
▼(-37.49% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.94% Insiders
19.16% Mutual Funds
11.15% Other Institutional Investors
36.64% Public Companies and Individual Investors